Iregene Therapeutics
- Biotech or pharma, therapeutic R&D
iRegene focuses on developing first-in-class chemically induced allogenic therapies for major incurable diseases, including Parkinson's disease, multiple system atrophy, retinal degenerative conditions, and other diseases. Our lead product, NouvNeu001, targeting Parkinson's disease, has successfully completed its Phase 1 clinical trial, demonstrating excellent safety, fast-acting properties, and significant disease-reversing effects. We have now initiated Phase 2 in China and Phase 1 in the US.
Our proprietary “AI + chem” induction platform has strong potential to generate additional pipelines with a favorable safety profile and a demonstrated purity rate above 99%.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}